A Refill on Relief: FDA Extends DSCSA Exemption for Small Dispensers as Assessment Begins

Background

The DSCSA was enacted in 2013 to build a more secure, traceable prescription drug supply chain and protect patients from harmful drugs. It applies to trading partners (pharmaceutical manufacturers, repackagers, wholesale distributors, and dispensers), and phased in requirements for enhanced drug distribution security, including secure, interoperable electronic DSCSA data exchange among trading partners in the US supply chain. The enhanced drug distribution security requirements took effect on November 27, 2023. Implementation required significant investment in technology, changes to business processes, staff training, and coordination with trading partners — operational demands that were challenging for many trading partners. The FDA responded by giving industry additional time to comply, including a targeted exemption for small dispensers that was set to expire on November 27 of this year. 

The FDA’s August 6 action effectively extends the small dispenser exemption to November 27, 2027. The DSCSA also requires the FDA to assess whether small dispensers can meet the enhanced electronic tracing requirements; the August 6 exemption is tied in part to giving the FDA time to complete that assessment and related public process. The FDA also announced the opening of the small dispenser assessment survey in connection with the new exemption.

What the Extended Exemption Means for Small Dispensers and Their Trading Partners

The August 6 action extends the existing FDA exemption for small dispensers until November 27, 2027. A qualifying small dispenser is a dispenser whose owning company, as of November 27, 2026, has 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians. Where applicable, the exemption also addresses small dispensers’ trading partners, allowing the parties to use current methods in lieu of meeting enhanced drug distribution and related requirements. The exemption is automatic; no FDA filing, application, or notification is required to rely on it. Affected parties should communicate reliance on the exemption as needed for operational clarity. 

The extended exemption is limited to certain enhanced DSCSA requirements, not a blanket pause of all DSCSA compliance. Small dispensers and their trading partners must still comply with non-exempt, longstanding DSCSA requirements. The FDA’s attention-garnering April 1 warning letter to Pure Indulgence Aesthetics underscores the point: Pure Indulgence operated as a DSCSA “dispenser,” and the FDA cited it for the inability to demonstrate transactions only with authorized trading partners and for transactions involving product lacking a required product identifier. The warning letter is illustrative of the FDA’s appetite for enforcing DSCSA requirements that are not covered by the exemption. (See our related client alert, All Filler, No Foundation: Pure Indulgence’s 483 Becomes a DSCSA Warning Letter.)

The Small Dispenser Assessment

The DSCSA directs the FDA to assess the feasibility of dispensers with 25 or fewer full-time employees conducting interoperable, electronic package-level tracing. The assessment focuses on small dispensers and examines whether the necessary software and hardware are accessible, affordable to obtain, install, and maintain, and capable of integration into small dispensers’ business practices.

The FDA encourages small dispensers to complete its assessment survey by September 22; a small dispenser may designate another entity to complete it on its behalf. The survey is a separate assessment effort, not an exemption application or condition to rely on the exemption. The DSCSA requires the FDA to consider the assessment in providing alternative methods of compliance, including adjusted timelines and a waiver process for undue economic hardship. After receiving the final assessment, the FDA must publish it for public comment within 30 calendar days and hold a public meeting within 180 calendar days.